SAR and QSAR in environmental researchEzetimibeDrug RepositioningAldo-Keto ReductasesMolecular Docking SimulationHumans
Targeting drug-resistant cancers: in silico repurposing of the cholesterol-lowering drug Ezetimibe for selective inhibition of aldo-keto reductase 1B10 (AKR1B10).
H J Alkhalaf, J Abdulrazzak Al Shehadeh, M K Alshjai, T Elsaman, M A Mohamed
Published: 202510.1080/1062936X.2025.2572105
Abstract
One of the major challenges in cancer treatment is drug resistance, often driven by overexpression of detoxifying enzymes such as aldo-keto reductase family 1 member B10 (AKR1B10). Highly expressed in several cancers, AKR1B10 contributes to chemother…
Preview only. Read the full abstract at the source